New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2013
07:48 EDTAVNRAvanir Pharmaceuticals receives CHMP opinion for approval of Nuedexta in Europe
Avanir Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta, recommending Nuedexta be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause. In addition, the CHMP also recommended approval of two dose strengths of Nuedexta; 20/10 mg and 30/10 mg capsules.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
08:37 EDTAVNRAvanir reports on dementia/Alzheimer's candidate Phase IV study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use